On May 12, 2020, Moderna announced the U.S. Food and Drug Administration (FDA had granted Fast Track designation for the Company’s mRNA vaccine candidate (mRNA-1273) against the novel coronavirus (SARS-CoV-2).

The Company intended to enroll 600 healthy participants across two cohorts of adults ages 18-55 years (n=300) and older adults ages 55 years and above (n=300). Each participant was assigned to receive placebo, a 50 ﾵg or a 250 ﾵg dose at both vaccinations. Participants were followed through 12 months after the second vaccination.